Please upgrade your browser
In order to have the best possible experience on www.valuepartners-group.com, we recommend that you upgrade to a newer version or switch to a different browser.
Currently browsing:


Value Partners Health Care Fund
(A UCITS Compliant Fund)

Other Funds

    • Risk Disclosure
      • Value Partners Health Care Fund (the “Fund”) primarily invests in equities and equity-related securities in healthcare companies on a worldwide basis.
      • The investments of the Fund are concentrated in the health care sector which are subject to greater influences from government policies and regulations than those of other industries. The value of the Fund may be more volatile than that of a fund having a more diverse portfolio of investments.
      • Investing in PRC market exposes the Fund to additional risks including currency repatriation risk, uncertainty of taxation policies and risk associated with Stock Connects. The Fund may also expose to RMB currency and conversion risk.
      • Investing in small/mid-capitalization securities may have lower liquidity and their prices are more volatile to adverse economic developments.
      • The Fund may also invest in derivatives and debt securities that are below investment grade or unrated which can involve material risks, e.g. counterparty default risk, insolvency or liquidity risk, and may expose the Fund to significant losses.
      • You should not make investment decision on the basis of this marketing material alone. Please read the prospectus for details and risk factors.

    Performance Updateas at 07-04-2021

    Performance Update

    Annual Returns

    Annual Returns

    Performance Since Launch as at 07-04-2021

    Performance Since Launch

    All indices are for reference only.

    Source: Source: HSBC Institutional Trust Services (Asia) Limited and HSBC Securities Services (Ireland) DAC, in US dollar, NAV to NAV, with dividends reinvested. Performance data is net of all fees.

    Please note that investment involves risks. The unit price of the Funds may go down as well as up and the past performance presented is not indicative of future performance and investors may not get back the full amount invested. Investors should refer to the explanatory memorandum of the Funds for further details and the risk factors in particular those involved in investing in emerging markets prior to the subscription of the units of the Fund.

     

     

    Investment objectives

    The Fund aims to achieve long-term capital growth by investing primarily in equities and equity-related securities in healthcare companies including pharmaceuticals, biotechnology, healthcare services and medical technology and supplies on a worldwide basis.

    Open-ended Umbrella Investment Company

    Value Partners Ireland Fund ICAV

    Promoter and investment manager

    Value Partners Hong Kong Limited

    Depositary

    HSBC Continental Europe

    Legal status

    Authorized by the Central Bank of Ireland as an Undertaking for Collective Investment in Transferable Securities (UCITS) pursuant to the European Communities UCITS Regulations 1

    Launch date

    02-04-2015

    Base currency

    US dollar

    Other currency class available

    AUD, AUD (hedged), CAD, CAD (hedged), Euro, Euro (hedged), GBP, GBP (hedged), HKD, NZD, NZD (hegded), RMB, RMB (hedged), SGD, SGD (hedged), USD 

    Minimum subscription

    AUD 10,000 / CAD 10,000 / EUR 10,000 / GBP 10,000 / HKD 80,000 / RMB 60,000/ SGD 10,000 / USD 10,000 / USD (Class Z) 10,000,000

    Initial subscription fee

    Up to 5% of the issue price

    Investment manager fees

    1.5% per annum

    1% per annum (for Class Z USD)

    Performance fee

    15% on high watermark 3

    Dealing frequency

    Daily, 11.59am Irish time

    Print

    1. Value Partners Ireland Fund ICAV (formerly Value Partners Ireland Fund plc) is authorized and supervised by the Central Bank of Ireland (“Central Bank”). Authorization by the Central Bank shall not constitute a warranty as to the performance of the ICAV and the Central Bank shall not be liable for the performance or default of the ICAV. Authorization of the ICAV is not an endorsement or guarantee of the ICAV by the Central Bank.
    2. Transactions for currency hedging purposes may be carried out in respect of shares in the Hedged Classes; for details on this and/or for a full list of share classes, please refer to the prospectus and the relevant fund supplement.
    3. Performance fees will only be charged if the NAV at the end of the financial year exceeds the “high watermark”, which is the all-time year-end high of the fund’s NAV. If in any one year, the fund suffers a loss, no performance fee can be charged in subsequent years until the loss is recovered fully (the high-on-high principle).

    Please note that investment involves risks. The unit price of the Fund(s) may go down as well as up and past performance of the Fund(s) does not indicate future return. Investors should refer to the Prospectus, Supplement(s) and Key Investor Information Document(s) of the Fund(s) for further details and the risk factors in particular those involved in investing in emerging markets prior to the subscription of the units of the Fund(s).

    
    Loading...
    Type of DocumentDateDownload
    From
    To
    Date

    USD Class Unhedged

    HKD Class Unhedged

    SGD Class A Unhedged

    • Risk Disclosure

      • Value Partners Health Care Fund (the “Fund”) primarily invests in equities and equity-related securities in healthcare companies on a worldwide basis.
      • The investments of the Fund are concentrated in the health care sector which are subject to greater influences from government policies and regulations than those of other industries. The value of the Fund may be more volatile than that of a fund having a more diverse portfolio of investments.
      • Investing in PRC market exposes the Fund to additional risks including currency repatriation risk, uncertainty of taxation policies and risk associated with Stock Connects. The Fund may also expose to RMB currency and conversion risk.
      • Investing in small/mid-capitalization securities may have lower liquidity and their prices are more volatile to adverse economic developments.
      • The Fund may also invest in derivatives and debt securities that are below investment grade or unrated which can involve material risks, e.g. counterparty default risk, insolvency or liquidity risk, and may expose the Fund to significant losses.
      • You should not make investment decision on the basis of this marketing material alone. Please read the prospectus for details and risk factors.
    • Performance

      Performance Update

      Performance Update

      Annual Returns

      Annual Returns

      Performance Since Launch as at 07-04-2021

      Performance Since Launch

    • Fund Facts

      Investment objectives

      The Fund aims to achieve long-term capital growth by investing primarily in equities and equity-related securities in healthcare companies including pharmaceuticals, biotechnology, healthcare services and medical technology and supplies on a worldwide basis.

      Open-ended Umbrella Investment Company

      Value Partners Ireland Fund ICAV

      Promoter and investment manager

      Value Partners Hong Kong Limited

      Depositary

      HSBC Continental Europe

      Legal status

      Authorized by the Central Bank of Ireland as an Undertaking for Collective Investment in Transferable Securities (UCITS) pursuant to the European Communities UCITS Regulations 1

      Launch date

      02-04-2015

      Base currency

      US dollar

      Other currency class available

      AUD, AUD (hedged), CAD, CAD (hedged), Euro, Euro (hedged), GBP, GBP (hedged), HKD, NZD, NZD (hegded), RMB, RMB (hedged), SGD, SGD (hedged), USD 

      Minimum subscription

      AUD 10,000 / CAD 10,000 / EUR 10,000 / GBP 10,000 / HKD 80,000 / RMB 60,000/ SGD 10,000 / USD 10,000 / USD (Class Z) 10,000,000

      Initial subscription fee

      Up to 5% of the issue price

      Investment manager fees

      1.5% per annum

      1% per annum (for Class Z USD)

      Performance fee

      15% on high watermark 3

      Dealing frequency

      Daily, 11.59am Irish time

      Print

      1. Value Partners Ireland Fund ICAV (formerly Value Partners Ireland Fund plc) is authorized and supervised by the Central Bank of Ireland (“Central Bank”). Authorization by the Central Bank shall not constitute a warranty as to the performance of the ICAV and the Central Bank shall not be liable for the performance or default of the ICAV. Authorization of the ICAV is not an endorsement or guarantee of the ICAV by the Central Bank.
      2. Transactions for currency hedging purposes may be carried out in respect of shares in the Hedged Classes; for details on this and/or for a full list of share classes, please refer to the prospectus and the relevant fund supplement.
      3. Performance fees will only be charged if the NAV at the end of the financial year exceeds the “high watermark”, which is the all-time year-end high of the fund’s NAV. If in any one year, the fund suffers a loss, no performance fee can be charged in subsequent years until the loss is recovered fully (the high-on-high principle).

      Please note that investment involves risks. The unit price of the Fund(s) may go down as well as up and past performance of the Fund(s) does not indicate future return. Investors should refer to the Prospectus, Supplement(s) and Key Investor Information Document(s) of the Fund(s) for further details and the risk factors in particular those involved in investing in emerging markets prior to the subscription of the units of the Fund(s).

    • Documents

      
      Loading...
      Type of DocumentDateDownload
    • Historical Prices

      From
      To
      Date

      USD Class Unhedged

      HKD Class Unhedged

      SGD Class A Unhedged

      From
      To
      Date

      USD Class Unhedged

      HKD Class Unhedged

      SGD Class A Unhedged